American Society of Hirudotherapy

Smart Library

Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.

Curated knowledge library: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.Reference collection: Content is historical, educational, or biographical reference material — not a clinical recommendation.

New to hirudotherapy? Start here

This library indexes the full evidence base. For orientation, begin with the core guides:

Conditions

3

Venous Congestion in Surgical Flaps

Tier A

FDA-cleared application: medicinal leech therapy to relieve venous congestion in compromised tissue flaps awaiting vascular ingrowth.

FDA-cleared device indication: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.FDA-cleared regulatory context

Microsurgical Replantation (Digit / Ear / Scalp)

Tier A

FDA-cleared application: post-replantation venous decompression in digits, ears, scalp, and partial avulsion injuries.

FDA-cleared device indication: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.FDA-cleared regulatory context

Breast Reconstruction Flap Salvage

Tier A

FDA-cleared application: venous decompression of compromised DIEP, TRAM, and latissimus dorsi flaps in post-mastectomy reconstruction.

FDA-cleared device indication: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.FDA-cleared regulatory context

Compounds

9

Bivalirudin

Synthetic 20-amino-acid hirudin analog — FDA-approved direct thrombin inhibitor for PCI anticoagulation ($636M peak revenue).

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Lepirudin

First-generation recombinant hirudin — FDA-approved 1998 for heparin-induced thrombocytopenia (HIT). Withdrawn 2012 by Bayer for commercial reasons.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Desirudin

Recombinant hirudin variant — FDA-approved 2003 for prophylaxis of DVT after hip replacement surgery.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Dabigatran

Oral direct thrombin inhibitor — FDA approved 2010 for stroke prevention in atrial fibrillation. Synthetic; designed from the inhibitor NAPAP, not derived from hirudin.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Argatroban

Synthetic small-molecule direct thrombin inhibitor — FDA approved 2000 for HIT, later also for PCI in patients with or at risk of HIT. Derived from arginine, not from hirudin.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Rivaroxaban

Oral Factor Xa inhibitor — FDA approved 2011. Synthetic (Bayer, oxazolidinone series); shares its target with the leech protein antistasin but is not derived from it.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Apixaban

Oral Factor Xa inhibitor — FDA approved 2012. Synthetic; shares its target with the leech protein antistasin but is not derived from it.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Edoxaban

Oral Factor Xa inhibitor — FDA approved 2015. Synthetic; shares its target with the leech protein antistasin but is not derived from it.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Eptifibatide

Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Designed from snake-venom barbourin; not derived from the leech.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Smart Library — Faceted Search Across All Registries | ASH